Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Regulatory News & FDA Approvals » FDA Clears NantHealth Tumor-Normal Whole-Exome Test

FDA Clears NantHealth Tumor-Normal Whole-Exome Test

Nov 12, 2019
|
staff reporter

NEW YORK – The US Food and Drug Administration has granted 510(k) clearance to NantHealth for its Omics Core technology, a whole-exome tumor-normal in vitro diagnostic that measures overall tumor mutational burden in cancer tissue and reports somatic mutations in 468 cancer-relevant genes.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Another Protocol Released

AstraZeneca has released its coronavirus vaccine trial protocol, according to the New York Times.

From Just Some Blood

Time magazine looks into how liquid biopsies are changing cancer care.

Numerous Countries Agree to Vaccine Plan

According to the Guardian, more than 150 countries have signed on to a global SARS-CoV-2 vaccine plan.

PNAS Papers on Hypertrophic Cardiomyopathy, Major Depression, Spanish SARS-CoV-2 Cat

In PNAS this week: similar muscle protein patterns across hypertrophic cardiomyopathy phenotypes, analysis of gene expression and brain anatomy in major depression, and more.

Oct
09
Featured Webinar

Navigating the FDA's EUA Process for Diagnostics in the Present and Future: A Stakeholder Panel Discussion

Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.

What's Popular?

In Regulatory News & FDA Approvals

  1. FDA Revises Emergency Use Authorization for Abbott Point-of-Care SARS-CoV-2 Test

  2. FDA Grants Emergency Use Authorization for GK Pharmaceuticals Coronavirus Test

  3. Roche Gets FDA Emergency Use Authorization for Rapid Coronavirus, Flu Test

  4. DiaSorin Receives CE Mark to Use Saliva Samples With COVID-19 Test

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.